SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-012930
Filing Date
2022-08-09
Accepted
2022-08-09 17:14:04
Documents
63
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q olma-20220630x10q.htm   iXBRL 10-Q 1917257
2 EX-10.1 olma-20220630xex10d1.htm EX-10.1 408431
3 EX-31.1 olma-20220630xex31d1.htm EX-31.1 13569
4 EX-31.2 olma-20220630xex31d2.htm EX-31.2 13604
5 EX-32.1 olma-20220630xex32d1.htm EX-32.1 10423
  Complete submission text file 0001558370-22-012930.txt   6869440

Data Files

Seq Description Document Type Size
6 EX-101.SCH olma-20220630.xsd EX-101.SCH 36499
7 EX-101.CAL olma-20220630_cal.xml EX-101.CAL 48856
8 EX-101.DEF olma-20220630_def.xml EX-101.DEF 111247
9 EX-101.LAB olma-20220630_lab.xml EX-101.LAB 378434
10 EX-101.PRE olma-20220630_pre.xml EX-101.PRE 269615
57 EXTRACTED XBRL INSTANCE DOCUMENT olma-20220630x10q_htm.xml XML 1005811
Mailing Address 512 2ND STREET, 4TH FLOOR SAN FRANCISCO CA 94107
Business Address 512 2ND STREET, 4TH FLOOR SAN FRANCISCO CA 94107 (415) 651-3316
Olema Pharmaceuticals, Inc. (Filer) CIK: 0001750284 (see all company filings)

IRS No.: 300409740 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39712 | Film No.: 221149405
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences